Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
Summary
The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.
Official title: A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2021-07-01
Completion Date
2026-07-01
Last Updated
2021-08-11
Healthy Volunteers
No
Interventions
DC vaccine
EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
Locations (1)
Department of hematology
Beijing, China